---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-001755"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:13:14.283652+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NeOnc to present Phase 1 dose-escalation data from NEO212 trial on March 4 call

## Summary
- Investor conference call scheduled for March 4, 2026 at 9:00 a.m. ET to present initial Phase 1 dose-escalation results from NEO212-01 trial.
- Phase 1 portion evaluated oral NEO212 in CNS malignancies; data includes safety, toxicity, PK, and regulatory next steps.
- Featured participants: Dr. Henry Friedman (Duke), Dr. Alexandra Miller (NYU Langone), plus NTHI management.
- NEO212 is a proprietary bioconjugated temozolomide platform with FDA Fast-Track and IND status for CNS cancers.
- No specific data disclosed in this release; full presentation will occur on the call.

## SEC filing metadata
- accession: 0001829126-26-001755
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912626001755/0001829126-26-001755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912626001755/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-001755
- JSON: https://secwatch.observer/filing/0001829126-26-001755.json
- Plain text: https://secwatch.observer/filing/0001829126-26-001755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.